We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

14 hedge funds and large institutions have $503K invested in Avenue Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

77% less capital invested

Capital invested by funds: $2.14M → $503K (-$1.64M)

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$62K
2
VF
Virtu Financial
New York
+$38.9K
3
TSS
Two Sigma Securities
New York
+$21.7K
4
TRCT
Tower Research Capital (TRC)
New York
+$7.47K
5
BlackRock
BlackRock
New York
+$4.49K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$1.32M
2
Millennium Management
Millennium Management
New York
-$38.9K
3
WAM
Warberg Asset Management
Illinois
-$9K
4
BRWA
B. Riley Wealth Advisors
Florida
-$6.73K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$218K – – –
Citadel Advisors
2
Citadel Advisors
Florida
$57K +$62K +83 +377%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$40K +$4.49K +6 +9%
BRWA
4
B. Riley Wealth Advisors
Florida
$30K -$6.73K -9 -14%
VF
5
Virtu Financial
New York
$28K +$38.9K +52 New
BlackRock
6
BlackRock
New York
$27K +$4.49K +6 +14%
TSS
7
Two Sigma Securities
New York
$25K +$21.7K +29 +161%
Wells Fargo
8
Wells Fargo
California
$23K – – –
UBS Group
9
UBS Group
Switzerland
$15K +$2.99K +4 +17%
TRCT
10
Tower Research Capital (TRC)
New York
$15K +$7.47K +10 +53%
EL
11
EMFO LLC
Florida
$12K – – –
Northern Trust
12
Northern Trust
Illinois
$7K – – –
Millennium Management
13
Millennium Management
New York
$6K -$38.9K -52 -84%
BNP Paribas Financial Markets
14
BNP Paribas Financial Markets
France
$4 – – –
NCM
15
Nantahala Capital Management
Connecticut
– -$1.32M -1,292 Closed
WAM
16
Warberg Asset Management
Illinois
– -$9K -9 Closed
Morgan Stanley
17
Morgan Stanley
New York
– +$747 +1 New

ATXI Hedge Fund Activity: Q1 2022 in Review

14 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q1 2022, worth a combined $503K — down 77% from $2.14M a quarter earlier.

Fund positioning in ATXI was balanced in Q1 2022: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $62K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $1.32M sold.

  • 14 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $503K of Avenue Therapeutics, Inc. Common Stock stock for Q1 2022, down 77% quarter-over-quarter.
  • 2 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q1 2022 and 2 closed out, a net change of 0 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q1 2022 was Citadel Advisors, an estimated $62K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q1 2022 was Nantahala Capital Management, an estimated $1.32M sold.

Based on aggregated 13F filings for Q1 2022.